BioPharma APAC: R‑biolin matches Novolin® R in pre‑clinical tests, gears up for 50× scale‑up and human trials
BioPharma APAC reports that rBIO’s lead biosimilar insulin candidate, R‑biolin, achieved bioequivalence to Novo Nordisk’s Novolin® R in animal studies—an important validation step that clears the path for a 50‑fold manufacturing scale‑up and the first‑in‑human trials planned for later this year.
FirstWord Pharma: rBIO steps in as big insulin makers scale back legacy products
Bioequivalence confirmed: Pre‑clinical data demonstrate pharmacokinetic and pharmacodynamic parity with Novolin® R.
As Major Insulin Producers Shift Focus, rBIO Steps Up to Address Potential Shortages
With leading insulin manufacturers pivoting toward higher‑margin GLP‑1 and analogue products, supplies of human‑insulin formulations risk further contraction. Houston‑based synbio firm rBIO today announced a 50× manufacturing scale‑up of its biosimilar candidate R‑biolin and plans to initiate human trials in 2H 2025—aiming to avert projected shortages and reduce global costs.
BioProcess Online: The path to producing an insulin biosimilar
In this technical feature, BioProcess Online sits down with rBIO co‑founder Cameron Owen and CSO Dr. Deenadayalan Bakthavatsalam to unpack the real‑world hurdles of turning laboratory success with R‑biolin into metric‑ton commercial output.
WIRED: Can a tiny biotech make insulin dirt‑cheap?
WIRED’s in‑depth feature brings rBIO’s mission to a mainstream tech audience, explaining how the company’s R‑biolin biosimilar could shake up a century‑old insulin supply chain and drive down costs for the 8 million US insulin‑dependent patients.